Lecithin:cholesterol acyltransferase (LCAT), the enzyme that esterifies cholesterol in blood, also esterifies other steroids at the 3␤-hydroxyl. These steroids, like cholesterol, are ⌬ 5 -3␤-hydroxysteroids, such as pregnenolone and dehydroepiandrosterone. One unusual LCAT substrate is the estrogen, estradiol, which is esterified at the 17␤-hydroxyl. The esterification of estradiol by LCAT has been reported to produce a powerful antioxidant that protects low density lipoprotein (LDL) from oxidation. We investigated the substrate specificity of LCAT, comparing the esterification of four different steroids (estradiol, estriol, testosterone, and 5-androstene-3␤,17␤-diol) by human LCAT in blood and by acyl-coenzyme A:acyltransferase in tissue (placenta and fat). Estradiol was esterified only at the D ring 17␤-hydroxyl group in both blood and tissue. In contrast, although testosterone has a D ring structure identical to that of estradiol, and it was esterified at the 17␤-hydroxyl by acyl-coenzyme A:acyltransferase in tissue, it was not esterified by LCAT. When 5-androstenediol was the substrate in the tissues, both the 3␤-and 17␤-esters were synthesized, but the major product was the 17␤-ester. Conversely, although 5-androstenediol was an excellent substrate for LCAT, only the 3␤-hydroxyl was esterified. No 17␤-ester was formed. The comparison of the esterification of estriol by acyl-coenzyme A:acyltransferase and LCAT was also surprising. In the tissues, estriol is esterified at both D ring hydroxyls, and both are esterified about equally. Although estriol is an extremely polar estrogen, it is esterified by LCAT, albeit at a very slow rate. Although again both D ring hydroxyls were esterified, the LCAT esterification site was mainly at the 17␤-hydroxyl. Esterification of estriol at the 17␤-hydroxyl in preference to the 16␣-hydroxyl is especially striking, because the 17␤-hydroxyl group is sterically shielded by the C-18 methyl group, making esterification at this position energetically much more difficult.
S
TEROIDS are esterified in tissues by an acyl-coenzyme A (acyl-CoA):acyltransferase(s). This enzyme is not the same one that esterifies cholesterol, cholesterol acyl-CoA: acyltransferase (1; for a recent review of steroid-esterification, see Ref. 2) . Even steroids that have the same A, B ring system (⌬ 5 -3␤-hydroxysteroids) as cholesterol and are esterified at the 3␤-hydroxyl, for example, dehydroepiandrosterone (DHEA), are esterified by a different enzyme. This contrasts with lecithin:cholesterol acyltransferase (LCAT), the enzyme in blood that catalyzes the transesterification of the fatty acyl group from the 2Ј-position of lecithin to the 3␤-hydroxyl of cholesterol, leading to the synthesis of cholesterol esters. LCAT esterifies both cholesterol and a limited number of other steroids. Although the acyl-CoA:acyltransferase(s) in cells is capable of esterifying a wide array of steroids (3) , there are only a few known substrates for LCAT. They are ⌬ 5 -3␤-hydroxysteroids [pregnenolone, DHEA, and 5-androstene-3␤,17␤-diol (Adiol)] and the estrogen, estradiol (E 2 ) (4). LCAT esterification of steroids, especially of ⌬ 5 -3␤-hydroxysteroids, might appear to be a fortuitous circumstance emanating from their structural similarity to cholesterol. However, E 2 is esterified at the C-17 hydroxyl in the D ring (5, 6) , the opposite end of the molecule from the 3-hydroxyl (the esterification site of cholesterol). The 17␤-hydroxyl is not only far removed from the C-3 hydroxyl, but it is also adjacent to and sterically shielded by the C-18 methyl group. Consequently, the 17␤-hydroxyl is esterified only with difficulty, illustrating that the LCAT esterification of E 2 cannot be rationalized simply by a structural similarity to cholesterol.
Recently, it has been shown that the esterification of E 2 in blood might serve an important physiological function in the prevention of heart disease (7). It is well known that men and postmenopausal women have a higher incidence of coronary artery disease compared to premenopausal women (8, 9) . The increased susceptibility to heart disease of both men and menopausal women is thought to be due to a lack of estrogen. In fact, postmenopausal women receiving estrogen replacement therapy have a decreased risk of cardiovascular disease (10, 11) . The antiatherogenic effect of estrogens is known to be complex, involving changes in the blood lipid profile as well as effects on blood vessels, etc. Another role estrogens may play in preventing heart disease is in the inhibition of low density lipoprotein (LDL) oxidation, a primary step in atheromatous plaque formation (12) . Several studies have demonstrated that estrogens directly inhibit the oxidation of LDL (13) (14) (15) . However, mol/L estrogen are needed to inhibit LDL oxidation in vitro, a concentration at least a thousand-fold greater than that found physiologically. This would seem to imply that this nongenomic action is without biological implication. Shwaery et al. showed that physiologically relevant concentrations of E 2 can have antioxidant effects on LDL. They found that LDL isolated from male plasma that had been incubated in vitro with 1 nmol/L E 2 is protected from oxidation (7). Importantly, they demonstrated that LCAT esterification of E 2 during the incubation with plasma was obligatory for LDL protection by E 2 . More recently, they showed that when estrone, which is not esterified by LCAT, is similarly incubated with plasma, the LDL is not protected from oxidation (16) . Thus, minute amounts of the nonpolar E 2 metabolites, E 2 -fatty acid esters (LE 2 ), 1 produced in blood by LCAT appear to have a pronounced antioxidative, cardioprotective function.
That E 2 itself is an antioxidant is not surprising, as it has a phenolic A ring similar to many other antioxidants, such as vitamin E. However, fatty acid esterification of E 2 at the 17␤-hydroxyl, a secondary alkyl hydroxyl, produces an antioxidant with an unusual potency. Apparently, there are unknown chemical and stereochemical constraints as well as enzymatic reactions that lead to physiologically produced antioxidants. The extraordinary potency of the estradiol ester metabolites as antioxidants led us to examine the specificity of the D ring esterification of estrogens. We investigated the site specificity of LCAT in comparison with that of acylCoA:acyltransferase(s). We analyzed the products of esterification by both LCAT in human blood and acyl-CoA:acyltransferase(s) in tissue of four steroids: estriol (E 3 ), E 2 , Adiol, and testosterone (Fig. 1) . These studies show a remarkable difference in the nature of the products formed by the two enzymes. The results demonstrate the specificity of the esterification of the estrogens and the potential of these unusual esters for important physiological roles.
Materials and Methods
The radioactive steroids, [2, 4, 6, The human tissues, omental fat, placenta, and blood were obtained from patients undergoing surgery for reasons unrelated to these studies. These protocols were approved by the human investigation committee of Yale University School of Medicine (New Haven, CT).
Chromatography
Thin layer chromatography (TLC) was performed using 0.25-mm thick silica gel plates (Merck, EM Science, Darmstadt, Germany) with the following solvent systems: T 1 , hexane-ethyl acetate (7:3); T 2 , CHCl 3 -ethanol (9:1); and T 3 , benzene-ethyl acetate (85:15). Esters of E 2 and E 3 were eluted from the plates with CH 2 Cl 2 -CH 3 OH (9:1); Adiol and testosterone esters (TL) were eluted with benzene-acetone (4:1). In all cases the silica gel was placed into a glass wool-plugged Pasteur pipette and eluted with 1 mL of the appropriate solvent mixture. The solvent was evaporated under N 2 , and the resulting residue was partitioned between 1 mL diethyl ether and 0.2 mL H 2 O. The ether layer containing the steroid esters was evaporated and analyzed as described. The partition between ether and H 2 O was necessary to remove traces of silica to which the esters can reabsorb. The HPLC systems (Waters Corp., Marlborough, MA) were: 1) an M-6000A pump equipped with a U6K injector, a model 440 absorbance detector; and 2) a model 600E pump equipped with a U6K injector, a 484 absorbance detector, and a model 730 Data Module. HPLC columns and solvents on a LiChrosphere 100 Diol column (250 ϫ 4.6 mm; Merck) used the following systems: system H 1 , CH 2 Cl 2 -isopropanol (23:2); system H 2 , isooctane-CH 2 Cl 2 (1:4); system H 3 , isooctane/ CH 2 Cl 2 (7:3); system H 4 , isooctane/CH 2 Cl 2 (2:3); system H 5 , isooctane/ CH 2 Cl 2 (4:1) on an Ultrasphere-Silica column (250 ϫ 4.6 mm; Altex, Beckman Coulter, Inc., Berkeley, CA); and system H 6 , isooctane-isopropanol (49:1). All HPLC systems were run at a flow rate of 1.0 mL/min. The internal standards of E 3 and E 2 fatty acid esters were detected by the HPLC UV detector at 280 nm, TL were detected at 254 or 240 nm, and Adiol esters were detected at 210 nm. 1 L as a prefix or suffix as in LE 2 , LE 3 , TL, or Adiol L, indicates the phrase "lipoidal derivative" (fatty acid esters) of estradiol, estriol, testosterone, and 5-androstenediol, respectively. (17), E 3 -16␣-oleate, and E 3 -17␤-stearate were synthesized as described previously (18) . There is no special significance to the use of the oleate ester (all of the different fatty acid esters behave similarly in the chromatographic systems used in these studies). Adiol-3␤-stearate was synthesized by esterification of DHEA followed by reduction of the 17-ketone with NaBH 4 (19) . Adiol-17␤-stearate was prepared by 1) protection of the 3␤-hydroxyl group of DHEA as a tert-butyldiphenylsilyl ether, 2) reduction of the 17-ketone to the 17␤-alcohol, 3) esterification with stearoyl chloride, and 4) deprotection of the 3-hydroxyl group (19) . Testosterone-17␤-stearate was synthesized by direct esterification of testosterone with stearoyl chloride in pyridine (20) .
Purification

Synthesis of steroid esters
E 2 -17␤-stearate
Saponification of E 3 esters
Each sample was dissolved in 0.5 mL CH 3 OH, and 0.1 mL 1 n KOH was added. The mixture was incubated at 50 C overnight. After incubation, the solution was neutralized with 1 n HCl. One milliliter of H 2 O was added, and the CH 3 OH was removed under N 2 . The aqueous residue was extracted twice with 5 mL ethyl acetate-ether (1:1). Controls were treated similarly, except that H 2 O was added to the incubation mixture instead of KOH. The organic extracts were combined and evaporated under N 2 , and the residue was chromatographed by TLC in system T 2 using E 3 , with E 3 -16␣-oleate and E 3 -17␤-stearate as standards. Fractions migrating with the standards were eluted and counted for radioactivity.
LCAT
Human blood was collected in heparinized tubes, and plasma was obtained by centrifugation at 5,000 ϫ g for 5 min. Unless otherwise stated, approximately 500,000 dpm (10 Ϫ8 mol/L, final concentration) of the 3 H-labeled steroid substrates were added to the incubation tube, and the solvent was evaporated under N 2 . Afterward, 150 L phosphate buffer, pH 7.4, and 50 L plasma were added to the tubes, and the mixture was incubated at 37 C for the indicated times. In some experiments 1 mmol/L DTNB was included. The incubation mixtures were then extracted as follows. For [ 3 H]E 2 , the enzymatic reaction was stopped by the addition of 0.8 mL CH 3 OH containing 200 g E 2 -17␤-stearate as the internal standard. The reaction mixture was then extracted twice with 2 mL hexane. The hydrocarbon layers were combined and dried under N 2 , and the residue was purified by TLC in system T 1 [ratio to front (R f ) ϭ 0.4]. E 2 esters were visualized under long wave UV light after spraying with primuline (21) . The area containing the internal standard was scraped from the plate, and the radioactivity was counted. For [ 3 H]E 3 , the reaction was stopped with 0.4 mL CH 3 OH containing 200 g each of E 3 -16␣-oleate and E 3 -17␤-stearate as internal standards. The reaction mixture was extracted twice, first with 0.8 mL CHCl 3 and then with 1.2 mL of the CHCl 3 layer from an equilibrated mixture of CH 3 OHCHCl 3 -H 2 O (1:2:1). The CHCl 3 layers were combined and evaporated, and the resulting residue was partitioned between 2 mL each of CH 3 OH-H 2 O (4:1) and isooctane-benzene (4:1). The hydrocarbon layer was removed, and the aqueous CH 3 OH layer was extracted again with 2 mL isooctane-benzene (4:1). The hydrocarbon fractions contain the E 3 esters, and they were combined and evaporated. The E 3 esters were purified either by TLC as described for the E 2 esters, but using system T 2 (R f ϭ 0.8), or by HPLC in system H 4 . In these systems the 16␣-and 17␤-esters are not separated. In some experiments, as indicated, after TLC, the 16␣-and 17␤-E 3 esters were resolved by HPLC using system H 6 . For [
3 H]testosterone, the enzymatic reaction was stopped by the addition of 0.8 mL CH 3 OH. The alcoholic mixture was extracted twice with 2 mL isooctane containing 50 g testosterone-17␤-stearate. The hydrocarbon layers were withdrawn, combined, and dried under N 2 . The residue was purified by TLC in system T 1 or by HPLC in system H 5 . For [ 3 H]Adiol, after the incubation, 200 g each of the internal standards Adiol-3␤-stearate and Adiol-17␤-stearate were added in CH 3 OH and extracted with isooctane as described above. After evaporation of the hydrocarbon layer under N 2 , the residue was purified by TLC in system T 3 (R f ϭ 0.3). The 17␤-and 3␤-esters were not separated in this system. Adiol esters were visualized under UV light after spraying with primuline. The fraction that comigrated with the internal standards was eluted from the plate and partitioned between water and diethyl ether, and the radioactivity in the ether layer was counted. To resolve the 3␤-and 17␤-esters, the TLC fraction was chromatographed by HPLC using system H 3 . The yields in the incubations with E 2 , E 3 , and testosterone were corrected for recovery of the internal standards as determined in the UV of the HPLC. Adiol incubations were corrected for the average recovery determined separately with radioactive Adiol esters.
Human tissue Acyl-CoA:acyltransferase(s)
Microsomal fractions from human placenta and fat were prepared as follows. The tissues were dissected free of extraneous matter and washed thoroughly in ice-cold saline buffered with 10 mmol/L phosphate buffer, pH 7.4, to remove blood. The tissue was minced, homogenized in 3 vol cold 0.25 mol/L sucrose solution with two separate 5-s bursts of a Polytron homogenizer (Brinkmann Instruments, Inc., Westbury, NY) and then centrifuged at 700 ϫ g for 10 min. The supernatant was centrifuged at 10,000 ϫ g for 20 min, and the resulting supernatant was centrifuged at 105,000 ϫ g for 60 min. The pellet was suspended in 0.1 mol/L phosphate buffer, pH 7.4, and recentrifuged at 105,000 ϫ g for 60 min. The resulting pellet was suspended in the phosphate buffer and stored at Ϫ70 C.
3 H-Labeled steroids were incubated with the acyl-CoA transferase in fat and placental microsomes using procedures that we previously described (1). The 3 H-labeled steroids (500,000 dpm, ϳ10 
Results
LCAT esterification
3 H]E 3 was incubated in human plasma with or without 1 mmol/L DTNB for several time periods over 24 h as indicated. The incubations were stopped at 0, 3, 6, 12, and 24 h, and aliquots were analyzed as described above. The residue obtained after extraction of the incubation mixture was purified by TLC in system T 2 . The area where the internal standards migrated was eluted and purified by HPLC in system H 4 . The two families of LE 3 , the 16␣-and 17␤-esters, were not resolved in systems T 2 or H 4 (22) . The fractions from the HPLC containing the internal standards were counted to quantify the formation of LE 3 . The results show the timedependent formation of a nonpolar metabolite that migrated with the E 3 ester standards (Fig. 2) . As also shown in Fig. 2 , the formation of the esters was almost completely inhibited by the LCAT inhibitor, DTNB. (Fig. 3) . LE 3 synthesis was determined by purification by TLC in system T 2 . [ 3 H]LE 2 was determined by TLC in system T 1 . In this experiment, the yield of [ 3 H]LE 2 was about 2.3%, whereas the yield of LE 3 was 0.15%. As shown in Fig. 3 
Characterization of LE 3
In another experiment, the nonpolar product [ 3 H]LE 3 , synthesized by incubation of [ 3 H]E 3 with human plasma for 24 h, was analyzed further to confirm its identification as LE 3 . The hydrocarbon phase from the incubation extract was purified by column chromatography with silica gel (see Materials and Methods). The 3 H-labeled metabolite was eluted from the column with CHCl 3 along with both internal standards (E 3 -17␤-stearate and E 3 -16␣-oleate). After evaporation, the residue was purified again by HPLC in system H 4 . All of the [ 3 H]LE 3 eluted from the column was coincident with the internal standards, at about 14 min. The [ 3 H]LE 3 was divided into two fractions: one was saponified with KOH and the other, the control, was incubated in parallel in aqueous alcohol. The reaction mixtures were neutralized, extracted, and purified by TLC in system T 2 . The fractions migrating with the standards of E 3 and the E 3 esters were extracted and counted. As shown in Fig. 4 , virtually all of the nonpolar 3 H-labeled product, LE 3 , was hydrolyzed to E 3 by alkaline treatment. Conversely, almost none of the [ 3 H]LE 3 was converted to E 3 in the control incubation with aqueous CH 3 OH. To confirm that the saponified 3 H-labeled material was E 3 , a further reverse isotope dilution experiment was performed, cocrystallization of the TLC purified 3 H-labeled saponification product with carrier E 3 . Approximately 600 dpm of the 3 H-labeled fraction extracted from the E 3 area of the TLC plate was added to 20.5 mg E 3 . The mixture was crystallized three times, and portions of each of the crystals and the residue of the mother liquor were weighed and counted. The results in Table 1 show that the specific activity of the crystals and residues in the mother liquors remained constant throughout each crystallization, confirming that the saponified compound was first by TLC in system T 2 and then by HPLC in system H 6 . This HPLC system separates the 16␣-and 17␤-esters of LE 3 (22) . As shown in Fig. 5b, [ 3 H]LE 3 was separated into two radioactive peaks in this system. Both peaks comigrated with the two internal standards, either E 3 -16␣-oleate or E 3 -17␤-stearate. In the experiment shown, [ 3 H]LE 3 is composed of 78% 17␤-esters and 22% 16␣-esters. In three experiments performed separately, the ratio of 17␤-esters to 16␣-esters of LE 3 was 3.2 Ϯ 0.1. Thus, E 3 is esterified predominantly at the 17␤-hydroxyl group by LCAT. A summary of all of the experiments is shown in Table 2 .
Adiol
Although Adiol is known to be esterified by LCAT (4, 23, 24) , the specific product has not been characterized. To determine the nature of the Adiol esters formed biosynthetically by LCAT, [ 3 H]Adiol was incubated overnight in human plasma with and without 1 mmol/L DTNB. An aliquot of the residue obtained after extraction of the incubation mixture was chromatographed by TLC in system T 3 (R f ϭ 0.3). Although the C-3 ester migrates slightly faster than the C-17 ester in this system, they are not cleanly separated. The area of the plate containing both standards was extracted as described above, and an aliquot of the residue was counted. In three separate experiments, the yield of esterification ranged between 5.1-8.6%. In the incubations with DTNB, the yield was 0.1%. The remainder of the extract was analyzed by HPLC in system H 3 , which separates the Adiol 3␤-and 17␤-esters (R t ϭ 13 and 16 min, respectively). As shown in Fig. 5d , all of the radioactivity migrated with the internal standard, Adiol-3␤-stearate. No [ 3 H]17␤-ester was observed. The same results were obtained in three separate experiments. Thus, the [ 3 H]Adiol fatty acid esters formed by LCAT are exclusively Adiol-3␤-fatty acid esters. Although Adiol is a substrate for LCAT, unlike E 2 and E 3 , it is not esterified at the 17␤-hydroxyl group.
Testosterone
The [
3 H]C-19 steroid was incubated in human plasma with or without 1 mmol/L DTNB and extracted as described above. The residue obtained from the extract of the incubation mixture was analyzed by HPLC in system H 5 (R t ϭ 14 min). Aliquots of each fraction were counted. No radioactivity was found in any of the fractions (see Fig. 5c ). Thus, despite having an enzymatically accessible 17␤-hydroxyl group, testosterone is not esterified by LCAT.
Acyl-CoA:acyltransferase(s)
The four 3 H-labeled steroidal substrates, E 2 , E 3 , testosterone, and Adiol, were incubated with the microsomal fraction from human placenta and fat with an acyl-CoA-generating system as described above. After incubation for 2 h at 37 C, the reaction mixtures were extracted and purified exactly as described for the LCAT experiments (representative results are shown in Fig. 5, e-h ). In general, the rate of esterification of the steroids was lower in placenta than in fat. In three separate experiments with different placental preparations, the yields were: for E 2 , from 0.25-0.5%; for E 3 , 0.1-0.15%; for testosterone, 0.15-0.2%; and for Adiol, 1-4%. The esters of E 3 and Adiol formed in the placenta were characterized as described in the LCAT experiments. For Adiol, the ratio of 17␤-to 3␤-esters (Ϯsd) was 1.1 Ϯ 0.2. For E 3 , the ratio of 17␤-to 16␣-esters was 0.94 Ϯ 0.04. In three separate experiments with different preparations of omental fat, the yields were: for E 2 , from 7.8 -10% (Fig. 5e) ; for E 3 , from 1.2-2.5%; for testosterone, from 2-3.6% (Fig. 5g) ; and for Adiol, 26 -31%. The esters of E 3 and Adiol formed in the fat were characterized. For E 3 , the ratio (Ϯsd) of 17␤-to 16␣-esters was 1.09 Ϯ 0.02 (Fig. 5f ). For Adiol, the ratio (Ϯsd) of 17␤-to 3␤-esters was 2.8 Ϯ 0.1 (Fig. 5h) . The results are summarized in Table 2 .
Discussion
LCAT esterification of ⌬ 5 -steroids as well as E 2 was reported by Jones and James in 1985 (4). Although many different steroids are esterified in tissues by acyl-CoA:acyltransferase(s) enzymes (25) , LCAT has a more limited capability. Most steroids that are esterified in tissues are not esterified in blood. For example, several C-19 steroids with 17␤-hydroxyl groups, such as testosterone (4) and 5␣-dihydrotestosterone, are not esterified by LCAT (4, 23, 24) . In addition, steroids containing a 3␣-hydroxyl group, such as androsterone, are also not esterified by LCAT (26) . This high substrate specificity makes it especially surprising that E 2 is esterified by LCAT, because other steroids with structurally similar D rings are not esterified. For example, as shown in Fig. 5c , under conditions where E 2 is readily esterified by LCAT at C-17, testosterone is not esterified despite also having a 17␤-hydroxyl group. Yet both steroids are esterified in placenta (results above) and fat. Human fat was chosen for these experiments because it seemed to be the most likely tissue to contain the highest steroid acyltransferase activity. We have previously shown that human fat has the highest concentration of LE 2 (27) , and that in male rats, fat and testes are the only tissues that contain TL (20) . As expected, placenta had much lower levels of acyltransferase activity than fat.
When LCAT esterification of E 2 was first discovered, it was assumed that E 2 was esterified at C-17 because the D ring hydroxyl had been shown to be the site of esterification in tissues (17) , and because estrone, which does not have a 17-hydroxyl group, is not esterified by either LCAT (4) or 3 was isolated and saponified, and the product was purified by TLC (Fig. 4) . The radioactive material migrating with the E 3 standard was combined with 20.5 mg authentic E 3 and crystallized slowly overnight three times from acetone and hexane. X 0 is the residue before crystallization. X n is the crystalline product from the nth crystallization. ML n is the residue left in the mother liquor from the nth crystallization.
acyl-CoA:acyltransferase(s) (28) . Later, we isolated and characterized endogenous LCAT-synthesized LE 2 from human ovarian follicular fluid and showed that it consisted solely of 17␤-fatty acid esters of E 2 (5). LE 2 in ovarian follicular fluid is synthesized by LCAT (6) .
The esterification of Adiol is especially interesting because, unlike other C-19 steroids such as testosterone, it is a known substrate for LCAT (4, 23, 24) . This C-19 steroid has received considerable interest because, contrary to what might be expected from its structure, it is an unusual estrogen (29 -31) . Adiol has two secondary hydroxyl groups, one at 3␤ and the other at 17␤, both of which are potentially esterifiable. There have been several studies of the esterification of Adiol by tissue acyl-CoA:acyl transferase. It has been shown that both the 3␤-and 17␤-fatty acid esters are synthesized. In human breast cancer microsomes, approximately equal amounts of the two esters are produced (32) . In studies with breast cancer cell lines, both esters of Adiol have also been identified. In one of these studies, it was reported that the 17␤-esters predominated (33) , whereas in another, the 3␤-esters were the major product (34) . In the present studies with human placental microsomes, the two families of esters were produced in approximately equal amounts, with slightly more of the 17␤-esters formed. In fat, the 17␤-esters were produced in a greater than 3:1 ratio. The difference in the rate of esterification of the two sites by placenta and fat may indicate that different acyl-CoA:acyltransferase(s) esterify the two hydroxyls and that the concentrations of the two enzymes are different in these tissues. Nevertheless, in both tissues the 17␤-hydroxyl group is efficiently esterified.
Although Adiol is known to be esterified by LCAT, the nature of the product has not been determined previously. We characterized by HPLC the esters of Adiol that were formed in plasma. As shown in Fig. 5d , large amounts of the C-3 esters were detected, but no 17␤-esters were found. Thus, unlike testosterone, Adiol is an excellent LCAT substrate, but it, too, is not esterified at C-17. The comparison of LCAT esterification to that of acyl-CoA:acyltransferase(s) of the C-19 steroids is especially remarkable because, in contrast to LCAT, the acyl-CoA:acyltransferase(s) in tissues esterifies the 17␤-hydroxyl of both testosterone and Adiol. E 3 is a poor substrate for LCAT. It is esterified at less than 10% the rate of E 2 . Nevertheless, the very fact that E 3 is esterified at all is surprising, because it is a very polar steroid. Shwaery et al. (16) also noted small amounts of a nonpolar metabolite formed in the incubation of E 3 with plasma, but the product was not characterized. E 3 is not only far more polar than the major LCAT substrate, cholesterol, but it is also more polar than most estrogens and their metabolites. This is shown by the fact that E 3 can be easily separated from most other aromatic steroids by a simple partition between benzene and an aqueous buffer (35) . With the exception of E 3 , this procedure extracts almost all of the estrogens into the hydrocarbon phase. The formation of the nonpolar E 3 metabolite in plasma is enzymatic; it increases with time, and it is inhibited by DTNB. As would be expected for LE 3 , the nonpolar product is saponified into E 3 , which was identified by both its chromatographic properties as well as cocrystallization with carrier E 3 . LCAT-synthesized LE 3 was characterized by HPLC, in a system that resolves the 16␣-and 17␤-esters. As shown in Fig. 5b , there was considerably more of the 17␤-ester than the 16␣-ester formed by LCAT (Ͼ3:1 respectively). In contrast to LCAT, the acyl-CoA:acyltransferase(s) in both fat and placenta (see Results) synthesizes about equal amounts of the two families of esters. We have previously found in another model system, rat lung microsomes, that the 16␣-hydroxyl is esterified in slightly greater amounts than the 17␤-hydroxyl (22) . The prevalence of the 17␤-esters in the LCAT esterification of E 3 is surprising, because although the enzyme can obviously esterify both D ring hydroxyls, the 16␣-hydroxyl is sterically much more accessible. The 17␤-hydroxyl is shielded by the C-18 methyl group, which makes esterification at this site energetically much more difficult than that at the 16␣-hydroxyl group. ⌬ 5 -3␤-Hydroxysteroid fatty acid esters produced in situ by LCAT in blood are bound exclusively to lipoproteins (36 -38) . E 2 -fatty acid esters also bind only to lipoproteins and to no other proteins in blood (39) . Bélanger et al. found that steroid esters, unlike cholesterol esters, do not require cholesterol ester transfer protein for transport from high density lipoprotein, where they are synthesized to LDL (40) . Furthermore, they showed that lipoprotein-bound steroid esters can be taken up into cells by lipoprotein receptors where they are hydrolyzed into the free steroid (41) (42) (43) . In this manner, circulating steroid esters can act as a reservoir of the free steroids and, thereby, a source of biologically active hormones.
The recent finding that LCAT-synthesized LE 2 acts as an extremely potent antioxidant points to an important physiological role for these E 2 -esters (7, 16) . It is known that LE 2 circulates in human female blood (27, 44) , albeit in low concentrations (ϳ10 pmol/L). The low concentration, in addi- The ratio is of the type of specific esters formed: a E 3 , 17␤-/16␣-and b Adiol, 17␤-/3␤-.
c For testosterone and E 2 ϩ or Ϫ designates that esterification (17␤-) did or did not occur respectively. The ratios are ϮSD (n ϭ 3 separate experiments).
tion to analytical complexities, have made accurate quantification difficult. Consequently, there is little known about the physiological control of circulating LE 2 . It appears that, as would be expected, there is a correlation between E 2 and LE 2 in blood (27) , and that the fatty acids comprising LE 2 , both biosynthetic (6) and endogenous (5) , are predominantly unsaturated. However, there are no rigorous studies of LE 2 levels or fatty acid composition in premenopausal or menopausal women, nor is anything currently known about the relationship of endogenous LE 2 to arteriosclerosis or any other pathological condition. These questions become important in light of the finding that E 2 esterification leads to a potent antioxidant protection of LDL, as this nongenomic action may be a major factor in the well known cardiovascular protection caused by estrogens. The present studies demonstrate that there is both stringent substrate and regiospecificity for LCAT esterification; only estrogens, not structurally similar C-19 steroids, are esterified in the D ring. The esterification of the sterically hindered 17␤-hydroxyl group of E 3 , as in E 2 , may illustrate a previously unrecognized steric requirement that leads to extraordinarily potent antioxidants.
